Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Obinutuzumab
Related studies linked through entity extraction aliases.
Obinutuzumab in Combination With GDP Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
- Status
- TERMINATED
- Phase
- PHASE2
A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia
- Status
- TERMINATED
- Phase
- PHASE3
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
- Status
- WITHDRAWN
- Phase
- PHASE1
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation
- Status
- COMPLETED
- Phase
- PHASE1
BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies
- Status
- TERMINATED
- Phase
- PHASE1